FDA Approval Insights: Ramucirumab/Erlotinib in EGFR+ Metastatic NSCLC
Season 3, Episode 18, Jul 06, 2020, 05:23 PM
In our exclusive interview, Edgardo S. Santos, MD, discusses the data that led to the approval of ramucirumab in combination with erlotinib and shares his thoughts on its utility in the frontline setting.